

LUD 5538.1 CIP - JEL/NDH (09807399)

Claim 139: The isolated nucleic acid molecule of claim 110, comprising SEQ ID NO: 8.

Claim 140: The isolated nucleic acid molecule of claim 110, consisting of SEQ ID NO: 7.

Claim 141: The isolated nucleic acid molecule of claim 110, consisting of SEQ ID NO: 6.

Claim 142: The isolated nucleic acid molecule of claim 110, consisting of SEQ ID NO: 7.

Claim 143: The isolated nucleic acid molecule of claim 110, consisting of SEQ ID NO: 8.

REMARKS

The preceding amendment is presented in accordance with 37 CFR § 1.121(h). Claims 110-143 will be pending.

The amendment address points 3 and 10 of the office action. The objections to claims 108 and 109 are obviated via the sequence listing. Applicants note that the sequence listing objection was not sent with the June 5 office action, but was telefaxed on June 12, 2001.

Prior to addressing the bases for rejecting the claims, it is worthwhile to discuss what the empirical evidence provided in the application shows.

In example 1, a melanoma cell line is discussed. The prior art describes how various members of the CT family of antigens are expressed by this cell. The cell was used to determine expression of other members of the family. It should be borne in mind that the term "CT antigen" is discussed in the specification.

The cells were studied, using the "SEREX" methodology. This method is known in the art. To perform SEREX, total RNA is removed from cells, converted to cDNA and, a cDNA library is constructed in a vector. In this case, " λ ZAP" was used. The λ ZAP cDNA library was then used to transform E. coli.

After E. coli are transformed, the transformed cells are used to screen samples for antibodies. Allogeneic samples were used in example 1. Essentially, one is determining if the

LUD 5538.1 CIP - JEL/NDH (09807399)

protein encoded by the cDNA used to transform the E. coli reacts with antibodies in the sample. One knows that the reaction is not with a "native" E. coli protein, because in the SEREX method, such antibodies are "stripped" prior to reaction with the transformants. Applicants refer the examiner to the references cited at page 5, i.e., Sahin, et al, Proc. Natl. Acad Sci USA 92:11810-11813, and U.S. Patent No. 5,698,396, both of which are incorporated by reference. Full details of the SEREX methodology are described in these references. Hence, one knows that, if there are any positives, the reactive protein was from the cDNA library.

The yield in this experiment was high, i.e., there were 65 positives.

Example 2 describes, simply, attempts to identify the positive materials. Standard methods were used.

Table 8, at page 8, shows that of the 65 positives 18 were known CT antigens. Hence, one knows from this that one can identify known members of the CT family. Ten sequences were not identifiable in public sequence libraries. There were also, 33 clones which belonged to the "KOC" family.

Examples 3 and 5 deal with CT antigen, i.e., "CT7." Please see US Patent No. 6,297,364.

Example 6 describes sequence analysis of the 33 members of the family found in the experiments of example 2. As this example makes manifestly clear, two different genes, referred to as KOC-2 and KOC-3 were identified. They were clearly not artifacts, because when a testicular cDNA library was analyzed, again using allogeneic samples, the molecules were found.

In example 7, the DNA expression pattern of the genes was studies. KOC-2 was found in normal tissue, but only testis and, with modification of the assay, in normal kidney cells. This is a "classic" CT expression pattern. As noted in the application, "CT" means "cancer/testis."

The KOC-3 gene was found to be expressed in both cancer and normal cells.

Now, the examiner has rejected all of claims 53-73, 80-84, 108 and 109, arguing that the claims are not supported by either "a specific substantial utility or a well-established utility."

The examiner states that "the specification fails to demonstrate a utility for the nucleic acids of SEQ ID NOS: 5-8, as the specification fails to correlated the presence of the protein encoded by SEQ ID NOS: 5-8 in clinical samples." The examiner then goes on to hypothesize that (i) antibodies can cross react with different proteins, and (ii) that the polynucleotides may

LUD 5538.1 CIP - JEL/NDH (09807399)

not be expressed due to any of a number of hypotheses. The examiner also states that "under conditions of recombinant expression, epitopes of KOC-2 and 3 which are not normally expressed in a patient within the context of MHC could be expressed by E. coli."

All of this is unproven speculation. The facts are the following. Something in the serum of patient NW38 reacted with a protein expressed by cDNA from an allogeneic source. Antibodies were present in the cancer patient's serum. They did not react with an E. coli protein because, as has been pointed out, supra, when SEREX is carried out, any reactivity with E. coli proteins is eliminated by use of controls. Again, the examiner is directed to the references which describe the SEREX methodology.

With respect to the elaborate argument regarding factors affecting translation of proteins, this is all well and good, but it is irrelevant. It is irrelevant because there were antibodies in the sample analyzed. Antibodies are produced in response to a protein. Hence, at some point, NW38 (the source of the sample), did have the protein in his or her blood. It got there by being expressed. The issue for CT antigens, as was set forth very clearly in the specification, is: are they expressed in individuals with cancer? The evidence indicates that KOC-2 and KOC-3 are so expressed, regardless of what happened to the irrelevant ferritin polypeptide, ornithine decarboxylase, and p glycoprotein discussed by the examiner, and not shown to be cancer antigens. With respect to the failure of protein and mRNA levels to correlate for p53, again, this is irrelevant. Applicants have not claimed a quantitative assay. The correct question is: is the molecule expressed in cancer patients and usable for diagnosis? The correlation of p53 with cancer is too well known to comment on.

With respect to the examiner's hypothetical argument that "antibodies bind to epitopes in proteins and antibodies can cross react with different proteins containing the same or similar proteins," this again ignores the evidence. In the SEREX methodology, antibodies against a host cell, e.g., E. coli, are removed in a stripping step. All that is left are antibodies which bind to non-E. coli proteins. Applicants used a cDNA library. It is well known that, when using a cDNA library, a single cDNA molecule is used as the transfectant. Hence, if an antibody reacts with a transfected or transformed cell, it must be reacting with the foreign protein, since antibodies to native proteins have been eliminated. Hence, all of the examiner's points are based upon generalizations which do not stand up to analysis when the data are considered. With respect to the statement bridging pages 4-5:

LUD 5538.1 CIP - JEL/NDH (09807399)

"The data indicating that the KOC-2 polynucleotide was restricted to the normal testis and that the KOC-3 polynucleotide was universal in normal tissues."

This is absolutely an incorrect reading of the data. First of all, there were antibodies against KOC-2 and KOC-3 found in the patient (NW38) sample. Hence, there was no immunotolerance. Second, the data state that "the only positive normal tissue was testis." These do not state that this was the only positive tissue. There is a very big difference. Further, if the examiner is going to argue that levels of expression can vary, then she must concede that, notwithstanding expression of KOC-3 in normal tissue, cancer tissues express it at a level such that an immune response is possible - especially since applicants have shown this.

Turning next to the rejection under 35 USC § 112, the statement of this rejection is not consistent. All claims are rejected, even though the examiner states that the claims are enabling for "polynucleotides comprising SEQ ID NOS: 5-8..." If this is the case, then claims 54-70 and 108 and 109 should not be rejected, as claims 54-70 expressly recite what is said to be enabled, and claims 108 and 109 have nothing to do with the issues raised in the rejection. The rejection recites points "A" and "B," and it is noted that only claims 53, 71-73 and 80-84 are rejected. They are no reasons given for rejecting the remaining claims.

Applicants contacted the examiner regarding this issue on October 22. The undersigned was advised that, if the utility rejection were overcome, then the issue at point 7 would be moot. It is noted that claims 54-70 are not rejected in the discussion following point 7. Claims 53 & 54 were combined to form claim 110. As such, claim 110 and claims dependent thereon cannot be rejected under 35 USC §112.

In view of the foregoing, allowance of this application is believed proper and is urged.

LUD 5538.1 CIP - JEL/NDH (09807399)

In view of the lack of clarity in this rejection, applicants cannot address it. The examiner is invited to clarify the rejection so it can be addressed. At such time, applicants will respond fully.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.



Norman D. Hanson, Esq.
Registration No. 30,946

666 Fifth Avenue
New York, New York 10103-3198
Telephone: 212-318-3168
Telecopier: 212-318-3400

<110> Chen, Yao-Tseng
 Gure, Ali
 Tsang, Solam
 Stockert, Elisabeth
 Jager, Elke
 Knuth, Alexander
 Old, Lloyd J.

<120> Isolated Nucleic Acid Molecules Encoding Cancer Associated Antigen, The
 Antigens Per Se, And Uses Thereof

<130> LUD 5538.1

<140> 09/270,437

<141> 1999 - 03 - 16

<150> 09/061,709

<151> 1998-04-17

<160> 23

C2
 <210> 1
 <211> 4265
 <212> DNA
 <213> Homo sapiens
 <220>
 <400> 1

GTCTGAAGGA CCTGAGGCAT	TTTGTGACGA GGATCGTCTC	AGGTCAGCGG AGGGAGGGAGA	60
CTTATAGACC TATCCAGTCT	TCAAGGTGCT CCAGAAAGCA	GGAGTTGAAG ACCTGGGTGT	120
GAGGGACACA TACATCCTAA	AAGCACCACA GCAGAGGAGG	CCCAGGCAGT GCCAGGAGTC	180
AAGGTTCCA GAAGACAAAC	CCCCTAGGAA GACAGGCGAC	CTGTGAGGCC CTAGAGCACC	240
ACCTTAAGAG AAGAAGAGCT	GTAAGCCGGC CTTTGTCTAGA	GCATCATGG GGGACAAGGA	300
TATGCCTACT GCTGGATGC	CGAGTCTTCT CCAGAGTTCC	TCTGAGAGTC CTCAGAGTTG	360
TCCTGAGGGG GAGGACTCCC	AGTCTCTCT CCAGATTCCC	CAGAGTTCTC CTGAGAGCGA	420
CGACACCTG TATCCTCTCC	AGAGTCCTCA GAGTCGTTCT	GAGGGGGAGG ACTCCTCGGA	480
TCCTCTCCAG AGACCTCCTG	AGGGGAAGGA CTCCCAGTCT	CCTCTCCAGA TTCCCCAGAG	540
TTCTCTCGAG GGGCACGACA	CCCAGTCTCC TCTCCAGAAT	TCTCAGAGTT CTCCAGAGGG	600
GAAGGACTCC CTGTCTCTC	TAGAGATTTC TCAGAGCCCT	CCTGAGGGTG AGGATGTCCA	660
GTCTCCTCTG CAGAATCCTG	CGAGTCCCTT CTTCTCCTCT	GCTTTATTGA GTATTTCCA	720
GAGTCCCCCT GAGAGTATTTC	AAAGTCCTT TGAGGGTTTT	CCCCAGTCG TTCTCCAGAT	780
TCCTGTGAGC GCGCCCTCT	CCTCCACTTT AGTGAAGTATT	TTCCAGAGTT CCCCTGAGAG	840
TACTCAAAGT CTTTGAGG	GTTTTCCCA GTCTCCACTC	CAGATTCCCTG TGAGCCGCTC	900
CTTCTCCTCC ACTTTATTGA	GTATTTCCA GAGTCCCCCT	GAGAGAAGTC AGAGAACTTC	960
TGAGGGTTTT GCACAGTCTC	CTCTCCAGAT TCCTGTGAGC	TCCTCCTCGT CCTCCACTTT	1020
ACTGAGTCTT TTCAGAGTT	CCCCCTGAGAG AACTCAGAGT	ACTTTTGAGG GTTTCCCCA	1080
GTCTCCACTC CAGATTCTG	TGAGCCGCTC TTCTCCTCC	ACTTTATTGA GTATTTCCA	1140
GAGTTCCCTC GAGAGAACTC	AGAGTACTTT TGAGGGTTTT	GCCCAGTCCTC CTCTCCAGAT	1200
TCCTGTGAGC CCCCTCTCT	CCTCCACTTT AGTGAAGTATT	TTCCAGAGTT CCCCTGAGAG	1260
AACTCAGAGT ACTTTGAGG	GTTTTCCCA GTCTCCCTC	CAGATTCCCTG TGAGCTCCTC	1320
CTTCTCCTCC ACTTTATTGA	GTCTTTCCA GAGTTCCCCCT	GAGAGAAGTC AGAGTACTTT	1380
TGAGGGTTTT CCCAGTCTC	CTCTCCAGAT TCCTGGAAGC	CCCTCCTCT CCTCCACTTT	1440
ACTGAGTCTT TTCAGAGTT	CCCCCTGAGAG AACTCACAGT	ACTTTTGAGG GTTTCCCCA	1500
GTCTCCTCTC CAGATTCTA	TGACCTCCTC TTCTCCTCT	ACTTTATTGA GTATTTACA	1560
GAGTTCTCCT GAGAGTGCTC	AAAGTGCTTT TGAGGGTTTT	CCCCAGTCCTC CTCTCCAGAT	1620
TCCTGTGAGC TCCTCTTCT	CCTACACTTT ATTGAGTCTT	TTCCAGAGTT CCCCTGAGAG	1680
AACTCACAGT ACTTTGAGG	GTTTTCCCCA GTCTCCCTC	CAGATTCCCTG TGAGCTCCTC	1740

C2
 6/ CTCCTCCTCC TCCACTTAT TGAGTCTTT CCAGAGTTCC CCTGAGTGTAC CTCAAAGTAC 1800
 TTTGAGGGT TTTCCCAGT CCTCTCTCCA GATTCTCTAG AGTCCTCTG AAGGGGAGAA 1860
 TACCCATTCT CCTCTCCAGA TTGTTCCAAG TCTTCCTGAG TGGGAGGACT CCTGCTCTC 1920
 TCACTACTT CCTCAGAGCC CCTCTCAGGG GGAGGACTCC CTATCTCTC ACTACTTCC 1980
 TCAGAGCCT CCTCAGGGGG AGGACTCCCT GTCTCTCCTAC TACTTCTC AGAGCCTCA 2040
 GGGGGAGGAC TCCCTGTCTC CTCACTACTT CCTCTCAGAGC CCTCTCAGGG GGGAGGACTC 2100
 CATGTCTCTC CTCTACTTTC CCTCAGAGTCC TCTTCAGGGG GAGGAATTCC AGTCTTCTCT 2160
 CCAGAGCCT GTGAGCATCT GTCCTCTC CACTCCATCC AGTCTTCCCC AGAGTTCTCC 2220
 TGAGAGTCT CAGAGTCTC TGAGGGGGC TGTCAGTCT CCTCTCCATA GTCCTCAGAG 2280
 CCTCTCTGAG GGGATGACT CCCAATCTCC TCTCCAGAGT CCTGAGAGTG CCTCTGAGGG 2340
 GGAGGATTCC CTGTCCTCTC TCCAAATTCC TCAGAGTCTT CTGAGGGAG AGGACTCCCT 2400
 GTCTCTCTC CATTTCCTC AGAGTCTCC TGAGTGGGAG GACTCCCTCT CCTCTCTCCA 2460
 CTTTCCTCAG TTTCCTCTC AGGGGGAGGA CTTCCAGTCT TCTCTCCAGA GTCCTGTGAG 2520
 TATCTGCTCC TCCTCCACTT CTTGAGTCT TCCCCAGAGT TTCCCTGAGA GTCCTCAGAG 2580
 TCCTCTGAG GGGCTGCTC AGTCTCTCTC CCAGAGACCT GTCACTCTC TCTCTCCTA 2640
 CACTTAGCG AGTCTTCTCC AAAGTTCCA TGAGAGTCT CAGAGTCTC CTGAGGGGCC 2700
 TGCCCACTG CCTCTCCAGA GTCCTGTGAG CTCCCTCCCC CCTCTCCACTT CATCGAGTCT 2760
 TCCCCAGAGT TCTCTGTGA GTCCTCTC CCTCTCCACT TCATCGAGTC TTCCAAGAG 2820
 TCCCCCTGAG AGTCTCTCC AGAGTCTGT GATCTCTTC CCTCTCTCCA TTTCATTGAG 2880
 CCCATTCACT GAAGAGTCCA GCAGCCCAGT AGATGAATAAT ACAAGTTCTC CAGACACCTT 2940
 GCTAGAGAGT GATTCTTGA CAGACAGCGA GTCCTGTATA GAGAGCGAGC CCTTGTTCAC 3000
 TTATACACTG GATGAAAAGG TGGACGAGTT GGCAGGGTTT CTTCTCTCA AATATCAAGT 3060
 GAAGCAGCCT ATCACAAAGG CAGAGATGTC GACGAATGTC ATCAGCAGGT ACACGGCTA 3120
 CTTTCTGTG ATCTCAGGA AAGCCCTGTA GTTCATAGAG ATACTTTTG GCATTCTCCT 3180
 GAGAGAAGTG GACCTGTATG ACTCTATGT CTTGTAAAC ACATTAGACC TCACCTCTGA 3240
 GGGGTGCTG AGTGTATGAGC AGGGCATGTC CCAGAACCGC CCTCTGTATT TTATCTGTGAG 3300
 TATCATCTC ATAAAGGGCA CCTATGCCCTC TGAGGAGGTC ATCTGGGATG TGCTGAGTGG 3360
 AATAGGGGTG CGTGTGGGA GGGAGCAGCT TGCCCTTGGG GAGCCCAGGG AGCTCTCAC 3420
 TAAAGTTGG GTGCAAGAAC ATTACCTAGA GTACCGGGAG GTGCCCAACT CCTCTCTCC 3480
 TCGTTACGAA TTCTGTGGG GTCCAAGAGC TCATTCAAGAA GTCATTAAGA GGAAAGTAGT 3540
 AGAGTTTTG GCCATGCTAA AGAATACCGT CCTATTACCT TTCCATCCTT CTTACAAGGA 3600
 TGCTTGTAAA GATGTGGAAG AGAGAGCCCA GGCCATAATG GACACCACAG ATGATTCGAC 3660
 TGCCACAGAA AGTCAAGCT CCAGTGTATG GTCCCCCAGC TTCTCTCTG AGTGAAGTCT 3720
 AGGGCAGATT CCTCCCTCTG AGTTGAAGG GGGCAGTCGA GTTCTACGT GGTGGAGGGC 3780
 CTGGITGAGG CTGGAGAGAA CACAGTGTCA TTTGCATTTC GTTCTCATAT GGGTAGTTAT 3840
 GGGGTTTACCT GTGTTTACTT TTGGGTATTT TTCAAATGCT TTCTCTATTA ATAACAGGTT 3900
 TAAATAGCTT CAGATCCTA GTTATGCAC ATGAGTCGCA CATGTATTGC TGTTTTCTG 3960
 GTTTAAGAGT AACAGTTGA TATTTGTAA AAACAAAAAC ACACCCAAAC ACACACATT 4020
 GGGAAAACCT TCTGCCTCAT TTGTGATGT GTCACAGGTT AATGTGGTGT TACTGTAGGA 4080
 ATTTTCTGAA AACTGTGAAG GAACTCTGCA GTTAAATAGT GGAATAAAAGT AAAGGATTGT 4140
 TAATGTTGCA ATTCCTCAG GTCTTTAGT CTGTTGTTCT TGAAAACCTAA AGATACATAC 4200
 CTGGTTTGCT TGGCTTACGT AAGAAAGTCG AAGAAAGTAA ACTGTAATAA ATAAAAGTGT 4260
 CAGTG 4265

<210> 2
 <211> 1142
 <212> PRT
 <213> Homo sapiens
 <220>
 <400> 2

Met Gly Asp Lys Asp Met Pro Thr Ala Gly Met Pro Ser Leu Leu Gln
 5 10 15
 Ser Ser Ser Glu Ser Pro Gln Ser Cys Pro Glu Gly Glu Asp Ser Gln
 20 25 30
 Ser Pro Leu Gln Ile Pro Gln Ser Ser Pro Glu Ser Asp Asp Thr Leu
 35 40 45
 Tyr Pro Leu Gln Ser Pro Gln Ser Arg Ser Glu Gly Glu Asp Ser Ser
 50 55 60
 Asp Pro Leu Gln Arg Pro Pro Glu Gly Lys Asp Ser Gln Ser Pro Leu

65 70 75 80
 Gln Ile Pro Gln Ser Ser Pro Glu Gly Asp Asp Thr Gln Ser Pro Leu
 85 90 95
 Gln Asn Ser Gln Ser Ser Pro Glu Gly Lys Asp Ser Leu Ser Pro Leu
 100 105 110
 Glu Ile Ser Gln Ser Pro Pro Glu Gly Glu Asp Val Gln Ser Pro Leu
 115 120 125
 Gln Asn Pro Ala Ser Ser Phe Phe Ser Ser Ala Leu Leu Ser Ile Phe
 130 135 140
 Gln Ser Ser Pro Glu Ser Ile Gln Ser Pro Phe Glu Gly Phe Pro Gln
 145 150 155 160
 Ser Val Leu Gln Ile Pro Val Ser Ala Ala Ser Ser Ser Thr Leu Val
 165 170 175
 Ser Ile Phe Gln Ser Ser Pro Glu Ser Thr Gln Ser Pro Phe Glu Gly
 180 185 190
 Phe Pro Gln Ser Pro Leu Gln Ile Pro Val Ser Arg Ser Phe Ser Ser
 195 200 205
 Thr Leu Leu Ser Ile Phe Gln Ser Ser Pro Glu Arg Ser Gln Arg Thr
 210 215 220
 Ser Glu Gly Phe Ala Gln Ser Pro Leu Gln Ile Pro Val Ser Ser Ser
 225 230 235 240
 Ser Ser Ser Thr Leu Leu Ser Leu Phe Gln Ser Ser Pro Glu Arg Thr
 245 250 255
 Gln Ser Thr Phe Glu Gly Phe Pro Gln Ser Pro Leu Gln Ile Pro Val
 260 265 270
 Ser Arg Ser Phe Ser Ser Thr Leu Leu Ser Ile Phe Gln Ser Ser Pro
 275 280 285
 Glu Arg Thr Gln Ser Thr Phe Glu Gly Phe Ala Gln Ser Pro Leu Gln
 290 295 300
 Ile Pro Val Ser Pro Ser Phe Ser Ser Thr Leu Val Ser Ile Phe Gln
 305 310 315 320
 Ser Ser Pro Glu Arg Thr Gln Ser Thr Phe Glu Gly Phe Pro Gln Ser
 325 330 335
 Pro Leu Gln Ile Pro Val Ser Ser Ser Phe Ser Ser Thr Leu Leu Ser
 340 345 350
 Leu Phe Gln Ser Ser Pro Glu Arg Thr Gln Ser Thr Phe Glu Gly Phe
 355 360 365
 Pro Gln Ser Pro Leu Gln Ile Pro Gly Ser Pro Ser Phe Ser Ser Thr
 370 375 380
 Leu Leu Ser Leu Phe Gln Ser Ser Pro Glu Arg Thr His Ser Thr Phe
 385 390 395 400
 Glu Gly Phe Pro Gln Ser Pro Leu Gln Ile Pro Met Thr Ser Ser Phe
 405 410 415
 Ser Ser Thr Leu Leu Ser Ile Leu Gln Ser Ser Pro Glu Ser Ala Gln
 420 425 430
 Ser Ala Phe Glu Gly Phe Pro Gln Ser Pro Leu Gln Ile Pro Val Ser
 435 440 445
 Ser Ser Phe Ser Tyr Thr Leu Leu Ser Leu Phe Gln Ser Ser Pro Glu
 450 455 460
 Arg Thr His Ser Thr Phe Glu Gly Phe Pro Gln Ser Pro Leu Gln Ile
 465 470 475 480
 Pro Val Ser Ser Ser Ser Ser Ser Thr Leu Leu Ser Leu Phe Gln
 485 490 495
 Ser Ser Pro Glu Cys Thr Gln Ser Thr Phe Glu Gly Phe Pro Gln Ser
 500 505 510
 Pro Leu Gln Ile Pro Gln Ser Pro Pro Glu Gly Glu Asn Thr His Ser
 515 520 525
 Pro Leu Gln Ile Val Pro Ser Leu Pro Glu Trp Glu Asp Ser Leu Ser
 530 535 540

Pro His Tyr Phe Pro Gln Ser Pro Pro Gln Gly Glu Asp Ser Leu Ser
 545 550 555 560
 Pro His Tyr Phe Pro Gln Ser Pro Pro Gln Gly Glu Asp Ser Leu Ser
 565 570 575
 Pro His Tyr Phe Pro Gln Ser Pro Gln Gly Glu Asp Ser Leu Ser Pro
 580 585 590
 His Tyr Phe Pro Gln Ser Pro Pro Gln Gly Glu Asp Ser Met Ser Pro
 595 600 605
 Leu Tyr Phe Pro Gln Ser Pro Leu Gln Gly Glu Phe Gln Ser Ser
 610 615 620
 Leu Gln Ser Pro Val Ser Ile Cys Ser Ser Ser Thr Pro Ser Ser Leu
 625 630 635 640
 Pro Gln Ser Phe Pro Glu Ser Ser Gln Ser Pro Pro Glu Gly Pro Val
 645 650 655
 Gln Ser Pro Leu His Ser Pro Gln Ser Pro Pro Glu Gly Met His Ser
 660 665 670
 Gln Ser Pro Leu Gln Ser Pro Glu Ser Ala Pro Glu Gly Glu Asp Ser
 675 680 685
 Leu Ser Pro Leu Gln Ile Pro Gln Ser Pro Leu Glu Gly Glu Asp Ser
 690 695 700
 Leu Ser Ser Leu His Phe Pro Gln Ser Pro Pro Glu Trp Glu Asp Ser
 705 710 715 720
 Leu Ser Pro Leu His Phe Pro Gln Phe Pro Pro Gln Gly Glu Asp Phe
 725 730 735
 Gln Ser Ser Leu Gln Ser Pro Val Ser Ile Cys Ser Ser Ser Thr Ser
 740 745 750
 Leu Ser Leu Pro Gln Ser Phe Pro Glu Ser Pro Gln Ser Pro Pro Glu
 755 760 765
 Gly Pro Ala Gln Ser Pro Leu Gln Arg Pro Val Ser Ser Phe Phe Ser
 770 775 780
 Tyr Thr Leu Ala Ser Leu Leu Gln Ser Ser His Glu Ser Pro Gln Ser
 785 790 795 800
 Pro Pro Glu Gly Pro Ala Gln Ser Pro Leu Gln Ser Pro Val Ser Ser
 805 810 815
 Phe Pro Ser Ser Thr Ser Ser Leu Ser Gln Ser Ser Pro Val Ser
 820 825 830
 Ser Phe Pro Ser Ser Thr Ser Ser Leu Ser Lys Ser Ser Pro Glu
 835 840 845
 Ser Pro Leu Gln Ser Pro Val Ile Ser Phe Ser Ser Ser Thr Ser Leu
 850 855 860
 Ser Pro Phe Ser Glu Glu Ser Ser Ser Pro Val Asp Glu Tyr Thr Ser
 865 870 875 880
 Ser Ser Asp Thr Leu Leu Glu Ser Asp Ser Leu Thr Asp Ser Glu Ser
 885 890 895
 Leu Ile Glu Ser Glu Pro Leu Phe Thr Tyr Thr Leu Asp Glu Lys Val
 900 905 910
 Asp Glu Leu Ala Arg Phe Leu Leu Lys Tyr Gln Val Lys Gln Pro
 915 920 925
 Ile Thr Lys Ala Glu Met Leu Thr Asn Val Ile Ser Arg Tyr Thr Gly
 930 935 940
 Tyr Phe Pro Val Ile Phe Arg Lys Ala Arg Glu Phe Ile Glu Ile Leu
 945 950 955 960
 Phe Gly Ile Ser Leu Arg Glu Val Asp Pro Asp Asp Ser Tyr Val Phe
 965 970 975
 Val Asn Thr Leu Asp Leu Thr Ser Glu Gly Cys Leu Ser Asp Glu Gln
 980 985 990
 Gly Met Ser Gln Asn Arg Leu Leu Ile Leu Ser Ile Ile Phe
 995 1000 1005
 Ile Lys Gly Thr Tyr Ala Ser Glu Glu Val Ile Trp Asp Val Leu Ser
 1010 1015 1020

Gly Ile Gly Val Arg Ala Gly Arg Glu His Phe Ala Phe Gly Glu Pro
 1025 1030 1035 1040
 Arg Glu Leu Leu Thr Lys Val Trp Val Gln Glu His Tyr Leu Glu Tyr
 1045 1050 1055
 Arg Glu Val Pro Asn Ser Ser Pro Pro Arg Tyr Glu Phe Leu Trp Gly
 1060 1065 1070
 Pro Arg Ala His Ser Glu Val Ile Lys Arg Lys Val Val Glu Phe Leu
 1075 1080 1085
 Ala Met Leu Lys Asn Thr Val Pro Ile Thr Phe Pro Ser Ser Tyr Lys
 1090 1095 1100
 Asp Ala Leu Lys Asp Val Glu Glu Arg Ala Gln Ala Ile Ile Asp Thr
 1105 1110 1115 1120
 Thr Asp Asp Ser Thr Ala Thr Glu Ser Ala Ser Ser Ser Val Met Ser
 1125 1130 1135
 Pro Ser Phe Ser Ser Glu
 1140

<210> 3
 <211> 7
 <212> PRT
 <213> Homo sapiens
 <220>
 <400> 3

Pro Gln Ser Pro Leu Gln Ile
 1 5

<210> 4
 <211> 4159
 <212> DNA
 <213> Homo sapiens
 <220>
 <400> 4

C2
 GGTGGATGCG TTTGGGTTGT AGCTAGGCTT TTCTTTTCT TTCTCTTTA AAACACATCT 60
 AGACACAAGGAA AAAACAAGCC TCGGATCTGA TTTTCACTC CTCGTTCTG TGCTGGTTC 120
 TTACTGTGTT TGTGTATTTT AAAGGCAGAGA AGACGAGGGG AACAAACCA GCTGGATCCA 180
 TCCATCACCG TGGGTGGTTT TAATTTTCG TTTTTCTCG TTATTTTTT TTAAACAACC 240
 ACTCTTCACA ATGAACAAAC TGTATATCGG AAACCTCAGC GAGAACGCCG CCCCTCGGA 300
 CCTAGAAAGT ATCTTCAGG ACGCCAAGAT CCCGGTGTG GGACCCCTCC TGGTGAAGAC 360
 TGGCTACGCG TTCTGGACT GCCCGGACGA GAGCTGGGCC CTCAAGGCCA TCGAGGCGCT 420
 TTCAGGTAAA ATAGAAACTGC ACGGGAAACC CATAGAAGTT GAGCACTCGG TCCCAAAAAG 480
 GCAAAGGATT CGGAAACTTC AGATACGAAA TATCCCGCCT CATTTCACAGT GGGAGGTGCT 540
 GGATAGTTA CTAGTCCAGT ATGGAGTGGT GGAGAGCTGT GAGCAAGTGA ACAGTGACTC 600
 GGAAACTGCA GTTGTAAATG TAACCTATTG CAGTAAGGAC CAAGCTAGAC AAGCACTAGA 660
 CAAACTGAAT GGATTTCACT TAGAGAATT CACCTTGAAA GTAGCCTATA TCCCTGATGA 720
 AATGGCCGCC CAGCAAAACC CCTTGAGCA GCCCGGAGGT CGCCGGGGGC TTGGGCAGAG 780
 GGGCTCCTCA AGGCAGGGGT CTCCAGGATC CGTATCCAAG CAGAACCAT GTGATTTGCC 840
 TCTGGCCCTG CTGGTTCCCA CCCAATTGTT TGGAGCCATC ATAGGAAAG AAGGTGCCAC 900
 CATTGGAAC ATCACCAAAAC AGACCCAGTC TAAATCGAT GTCCACCGTA AAGAAAATGC 960
 GGGGGCTGCT GAGAAGTGC A TTACTATCCT CTCTACTCCT GAAGGCACCT CTGCGGCTTG 1020
 TAAGTCTATT CTGGAGATTA TGCAATAAGGA AGCTCAAGAT ATAAAATCA CAGAAGAGAT 1080
 CCCCTTGAG ATTCTAGCTC ATAATAACTT TGTGGACGT CTTATTGTT AAGAAGGAAG 1140
 AAATCTTAAA AAAATTGAGC AAGACACAGA CACTAAAATC ACGATAATCTC CATTCAGGA 1200
 ATTGACGCTG TATAATCCAG AACGCACTAT TACAGTTAAA GGCAATGTT AGACATGTGC 1260
 CAAAGCTGAG GAGGAGATCA TGAAGAAAAT CAGGGAGTCT TATGAAAATG ATATTGCTTC 1320
 TATGAATCTT CAAGCACATT TAATTCCCTGG ATTAATCTG AACGCCTTGG GTCTGTTCCC 1380

ACCCACTTCA GGGATGCCAC CTCCCACCTC AGGGCCCCCT TCAGCCATGA CTCCTCCCTA 1440
 CCCGCAGTTT GAGCAATCAG AAACGGAGAC TGTTCATCAG TTATCCCCAG CTCTATCAGT 1500
 CGGTGCCATC ATCGGCARGC AGGGCCAGCA CATCAAGCAG CTTCTCGCT TTGCTGGAGC 1560
 TTCATTAAAG ATTGGTCCAG CGGAAGCACC AGATGCTAA GTGAGGATGG TGATTATCAC 1620
 TGGACCACCA GAGGCTCAGT TCAAGGCTCA GGGAAAGAATT TATGGAAAAA TTAAAGAAGA 1680
 AAACCTTGTG AGTCCTAAAG AAGAGGTGAA ACTTGAAGCT CATATCAGAG TGCCATCCTT 1740
 TGCTGCTGGC AGACTTATTG GAAAGGAGG CAAACGGTG AATGAACCTTC AGAATTGTC 1800
 AAGTGCAGAA GTTGTGTCC CTCGTGACCA GACACCTGAT GAGAATGACC AAGTGGTTGT 1860
 CAAAATAACT GGTCACTTCT ATGCTTGCCTA GGTTGCCAG AGAAAAAATTG AGGAAATTCT 1920
 GACTCAGGTA AAGCAGCACC ACAACAGAA GGCTCTGCAA AGTGGACCAC CTCAGTCAG 1980
 ACGGAAGTAA AGGCTCAGGA ACAGCCAC CACAGAGGCA GATGCCAAAC CAAAGACAGA 2040
 TTGCTTAAACC AACAGATGGG CGCTGACCCC CTATCCAGAA TCACATGCAC AAGTTTTAC 2100
 CTAGCCAGTT GTTCTGAGG ACCAGGCAAC TTTTGAACCTC CTGCTCTGT GAGAATGTAT 2160
 ACTTTATGCT CTCTGAAATG TATGACACCC AGCTTTAAA CAAACAAACA ARCAAACAAA 2220
 AAAAGGGTGG GGGAGGGAGG GAAAGAGAAG AGCTCTGCAC TTCCCTTTGT TGTAGTCTA 2280
 CAGTATAACA GATATTCTAA TTCTTCTTAA TATTCCCCA TAATGCCAGA AATTGGCTTA 2340
 ATGATGCTT CACTAAATTG ATCAAATAGA TTGCTCTAA ATCCAATTGT TAAATTGGA 2400
 TCAGAATAAT TATCACAGGA ACTTAAATGT TAAGCCATTA GCATAGAAAA ACTGTTCTA 2460
 GTTTTATTT TACCTAACAC TAACATGAGT AACCTAAGGG AAGTGTGAA TGGTGTGGC 2520
 AGGGGTATTA AACGTGCATT TTTACTCAAC TACCTCAGGT ATTCACTAAT ACAATGAAAA 2580
 GCAAAATTGT TCCTTTTTT TGAAAATTAT ATATACTTAA TAATGATAGA AGTCCAACCG 2640
 TTTTTAAA AATAAATTAA AAATTAAACA GCAATCAGCT AACAGGCAA TTAAGATTT 2700
 TACTCTGGC TGGTGCAGT AAAGCTGGAA AATTAATTTC AGGGTTTTT GAGGCTTTG 2760
 ACACAGTAT TAGTAAATC AAATGTCAA AAATACGGAG CAGTGCCTAG TATCTGGAGA 2820
 GCAGCACTAC CATTATTCTT TTCAATTATA GTTGGGAAAG TTTTGACGG TACTAACAAA 2880
 GTGGTCGAG GAGATTTGG AACGGCTGGT TAAATGGCT TCAGGAGACT TCAGTTTTT 2940
 GTTTAGCTAC ATGATTGAAT GCATAATAAA TGCTTGTGC TTCTGACTAT CAATACCTAA 3000
 AGAAAAGTCA TCAGTGAAGA GATGCAAGAC TTTCAACTGA CTGGCAAAA GCAAGCTTTA 3060
 GCTTGTCTTA TAGGATGCTT AGTTGCCAC TACACTTCAG ACCAATGGGA CAGTCATAGA 3120
 TGGTGTGACA GTGTTAACAC GCAACAAAG GCTACATTTC CATGGGGCCA GCACTGTCT 3180
 GAGCCTCACT AAGCTATTT GAAGATTTT AAGCACTGAT AAATTAAAAA AAAAAAAA 3240
 AAATTAGACT CCACCTTAAG TAGTAAAGTA TAACAGGATT TCTGTATACT GTGCAATCAG 3300
 TTCTTGAAA AAAAGTCAA AAGATAGAGA ATACAAGAAA AGTTTNGGG ATATAATTG 3360
 AATGACTGT AAAACATATG ACCTTTGATA AGCAACTCAT TTGCTCACTC CTTGACAGCA 3420
 AAGCCCAGTA CGTACAATTG TGTGGGGTGT GGGGGTCTC CAAGGCCACG CTGCTCTCTG 3480
 AATTGATTT TTGAGTTTG GNTTGNAGA TGATCACAGN CATGTTACAC TGATCTTNA 3540
 GGACATATNT TATAACCCCT TAAAAAAA ATCCOCTGCC TCATTCTTAT TTCGAGATGA 3600
 ATTCGATAC AGACTAGATG TCTTTCTGAA GATCAATTAG ACATTNTGAA AATGATTAA 3660
 AGTGTTCCTTCA TTATGTTCT CTGAAAACAA GTTCTTTTG TAGTTTAAC CAAAAAAAGTG 3720
 CCCTTTTGT CACTGGTTTC TCCTAGCATT CATGATTTT TTTTCACACA ATGAATTAAA 3780
 ATTCCTAAA TCATGGACTG GCTTTCTGGT TGGATTCAG GTAAGATGTG TTTAAGGCCA 3840
 GAGCTTTCT CAGTATTGAA TTTTTTCCC CAATATTGA TTTTTTAAA ATATAACACAT 3900
 AGGAGCTGCA TTAAACACCT GCTGGTTAA ATTCTGTCAATTTCACTTC TAGCCTTTA 3960
 GTATGCCNAA TCANAATTAA CTTTTACTTA AGCATTTGTA ATTTGGAGTA TCTGGTACTA 4020
 GCTAAGAAAT AATTCNATAA TTGAGTTTG TACTCNCCAA ANATGGGTCA TTCCTCATGN 4080
 ATAATGTNCC CCCAATGCAG CTTCAATTTC CAGANACCTT GACCGCAGGAT AAATTTTTC 4140
 ATCATTAGG TCCCCAAA 4159

C1
 C2

 <210> 5
 <211> 1708
 <212> DNA
 <213> Homo sapiens
 <220>
 <400> 5

AGGGACGCTG	CCGCACCGCC	CCAGTTTAC	CCGGGGAGCC	ATCATGAAGC	TGAATGGCCA	60
CCAGTTGGAG	AACCATGCC	TGAAGGTCTC	CTACATCCCC	GATGAGCAGA	TAGCACAGGG	120
ACCTGAGAAT	GGGCGCCGAG	GGGGCTTTGG	CTCTCGGGGT	CAGCCCCGCC	AGGGCTCACC	180
TGTGGCAGCG	GGGGCCCCAG	CCAAGCAGCA	GCAAGTGGAC	ATCCCCCTTC	GGCTCCTGGT	240

GCCCACCCAG TATGTGGGTG CCATTATTGG CAAGGGAGGGG GCCACCATCC GCAACATCAC 300
 AAAACAGACC CAGTCCAAGA TAGACGTGCA TAGGAAGGGG AACGCAGGTG CAGCTGAAAA 360
 AGCCATCAGT GTGCACTCCA CCCCTGAGGG CTGCTCCTCC GCTGTAAAGA TGATCTTGG 420
 GATTATGCAT AAAGAGGCTA AGGACACCAA AACGGCTGAC GAGGTTCCCC TGAAGATCCT 480
 GGCCATAAT AACTTTGTAG GGCGTCTCAT TGGCAAGGAA GGACGGAACC TGAAGAAGGT 540
 AGAGCAAGAT ACCGAGACAA AAATACCATC CTCCTCGTT CAAGACCTTA CCCTTACAA 600
 CCCTGAGAGG ACCATCACTG TGAAAGGGGG CATCGAGAAT TGTGCAAGGG CCGAGCAGGA 660
 ATAATGAAG AAAGTTCGGG AGGCCTATGA GAATGATGTG GCTGCCATGA GCTCTCACCT 720
 GATCCCTGGC CTGAACCTGG CTGCTGTAGG TCTTTTCCC GCTTCATCCA GCGCAGTCCC 780
 GCCGCCTCCC AGCAGCGTTA CTGGGGCTGC TCCCTATAGC TCCTTTATGC AGGCTCCCGA 840
 GCAGGAGATG GTGCAAGGTGT TTATCCCCGC CCAGGCAGTG GGCGCCATCA TCGGCAAGAA 900
 GGGGCAGCAC ATCAAACAGC TCTCCCGTT TGCCAGCGCC TCCATCAAGA TTGCACCAACC 960
 CGAACACCT GACTCCAAG TTCGTATGGT TATCATCACT GGACCGCCAG AGGCCAATT 1020
 CAAGGCTCAG GGAAGAATCT ATGGCAAAC CAAGGAGGAG AACTTCTTTG GTCCCAAGGA 1080
 GGAAGTGAAG CTGGAGACCC ACATACGTGT GCCAGCATCA GCAGCTGGCC GGGTATTGG 1140
 CAAAGGTGGA AAAACGGTGA ACGAGTTGCA GAATTGACG GCAGCTGAGG TGGTAGTACC 1200
 AAGAGACCAAG ACCCTGATG AGAACGACCA GGTCACTCGTGA AAAATCATCG GACATTCTA 1260
 TGCCAGTCAG ATGGCTAAC GGAAGATCCG AGACATCCTG GCCCAGGTTA AGCAGCAGCA 1320
 TCAGAAGGGGA CAGAGTAACC AGGCCCAGGC ACGGAGGAAG TGACCAAGCC CTCCCTGTCC 1380
 CTTNGAGTCC AGGACAACAA CGGGCAGAAA TCGAGACTGT GCTCTCCCCG GCAGGCCTGA 1440
 GAATGAGTGG GAATCAGGGG CAACNTGGGC GGGCTGTAGA TCAAGGTTGCG CCACTTGATT 1500
 SAGAAAGATG TTCCAGTGG GAACCCCTGAT CTNTCAGCCC CAAACACCCA CCCAATTGGC 1560
 CCAACACTGT NTGCCCTCG GGGTGTCAAGA AATTNTAGCG CAAGGCACTT TTAAACGTGG 1620
 ATTGTTAAA GAAGCTCTCC AGGCCCCAACC AAGAGGGTGG ATCACACCTC AGTGGGAAGA 1680
 AAAATAAAAT TTCCCTCAGG TTTTAAAAA 1708

<210> 6
 <211> 3412
 <212> DNA
 <213> Homo sapiens
 <220>
 <400> 6

C2
 4
 GGCAGCGGAG GAGGCGAGGA GCGCCGGGT ACGGGCCGGG GGAGCCGGGG GCTCTCGGGG 60
 AAGAGACGGA TGATGAACAA GCTTACATC GGGAACCTGA GCCCCCGCCGT CACCGCCGAC 120
 GACCTCCGGC AGCTCTTGG GGACAGGAAG CTGCCCCCTGG CGGGACAGGT CCTGCTGAAG 180
 TCCGGCTACG CCTTCTGTGA CTACCCCGAC CAGAACTGGG CCATCCCGCGC CATCGAGACC 240
 CTCTCGGGTA AAGTGGAAAT GCATGGGAAA ATCATGGAAG TTGATTACTC AGTCTCTAAA 300
 AAGCTAAGGA GCAGGAAAT TCAGATTGCA AACATCCCTC CTCACCTGCA GTGGGAGGTG 360
 TTGGATGGAC TTTGGCTCA ATATGGGACA GTGGAGAATG TGGAAACAAGT CAACACAGAC 420
 ACAGAAACCG CGGTGTCAA CGTCACATAT GCAACAAGAG AGAAGGCAA AATAGCCATG 480
 GAGAAGCTAA GCGGGCATCA GTTGGAGAAC TACTCCTCA AGATTTCTA CATCCCGGAT 540
 GAGAGGGTGA GCTCCCCCTC GCCCCCTCAG CGAGGCCAGC GTGGGGACCA CTCTTCCCGG 600
 GAGCAAGGCC ACGGCCCTGG GGGCACTTCT CAGGCCAGAC AGATTGATT CCCGCTGCGG 660
 ATCCCTGGTCC CCACCCAGTT TGTGGTGCC ATCATCGGA AGGGGGCTT GACCATAAAG 720
 AACATCACTA AGCAGACCA GTCCCGGGTA GATATCCATA GAAAAGAGAA CTCTGGAGCT 780
 GCAGAGAAGC CTGTCACCAT CCATGCCACC CCAGAGGGGA CTTCTGAAGC ATGCCGCATG 840
 ATTCTGAAA TCATGCAAGA AGAGGCAGAT GAGACCAAAC TAGCCGAAGA GATTCCCTTG 900
 AAAATCTGG CACACAATGG CTTGGTTGGA AGACTGATTG GAAAAGAAGG CAGAAATTG 960
 AAGAAAATTG AACATGAAAC AGGGACCAAG ATAACAATCT CATCTTGTCA GGATTGAGC 1020
 ATATACAACC CGGAAAGAAC CATCACTGTG AAGGGCACAG TTGAGGCCCTG TGCCAGTGCT 1080
 GAGATAGAGA TTATGAAGAA GCTGCGTGG AGCCTTGAAA ATGATATGCT GGCTGTTAAC 1140
 CAACAAGCCA ATCTGATCCC AGGGTTGAAC CTCAGCGCAC TTGGCATCTT TTCAACAGGA 1200
 CTGCTCCGTG TATCTCCACC AGCAGGGCCC CGGGGAGCTC CCCCCGCTGC CCCCTACAC 1260
 CCCTTCACTA CCCACTCCGG ATACTTCTCC AGCCTGTACC CCCATCACCA GTTTGGCCCG 1320
 TTCCCCCATC ATCACTCTTA TCCAGAGCAG GAGATTGTGA ATCTCTTCA CCCAACCCAG 1380
 GCTGTGGGCG CCATCATCGG GAAGAAGGGG GCACACATCA AACAGCTGGC GAGATTGCGC 1440
 GGAGCCCTCTA TCAAGATTGC CCCTGCGGAA GGCCAGACG TCAGCGAAAG GATGGTCATC 1500
 ATCACCGGGC CACCGGAAGC CCAGTTCAAG CCCAGGGAC GGATCTTGG GAAACTGAAA 1560

GAGGAAAAC TCTTTAACCC CAAAGAAGAA GTGAAGCTGG AAGCGCATAT CAGAGTGC 1620
 TCTTCCACAG CTGGCCGGGT GATTGGAAA GGTGGCAAGA CCGTGAACGA ACTGCAGAAC 1680
 TTAACCAGTG CAGAAAGTCAT CGTGCCTCGT GACCAACCGC CAGATGAAA TGAGGAAGTG 1740
 ATCGTCAGAA TTATCGGGCA CTTCTTGCCT AGCCAGACTG CACAGCGAA GATCAGGGAA 1800
 ATTGTACAAAC AGGTGAAGCA GCAGGAGCAG AAATACCCCTC AGGGAGTCGC CTCACAGCGC 1860
 AGCAAGTGAAG GCTCCACAG GCACCGAGCA AACAAACGGAT GAATGTAGCC CTTCCAACAC 1920
 CTGACAGAAT GAGACCAAAAC GCAGCCAGCC AGATCGGGAG CAAACCAAAG ACCATCTGAG 1980
 GAATGAGAAG TCTGCGGAGG CGGCCAGGGG CTCTGCCGAG GCCCTGAGAA CCCCAGGGC 2040
 CGAGGAGGGG CGGGGAAGGT CAGCCAGGTT TGCCAGAAC ACCGAGCCCC GCCTCCCGCC 2100
 CCCCAGGGCT TCTGCAGGCT TCAGCCATCC ACTTCACCAT CCACTCGGAT CTCTCCGTGAA 2160
 CTCCCACGAC GCTATCCCTT TAGTTGAAC TAACATAGGT GAACTGTGTC AAAGCCAAGC 2220
 AAAATGCACA CCCTTTTCT GTGGCAAATC GTCTCTGTAC ATGTGTGTC ATATTAGAAA 2280
 GGGGAAGATGT TAAGATATGT GGCCTGTGGG TTACACAGGG TCCCTGCAGC GGTAAATATAT 2340
 TTTAGAAAATA ATATATCAA TAACTCACACT AACTCCAATT TTAAATCAAT TATTAATTT 2400
 TTTTCTTTT TAAAGAGAAA GCAGGCTTT CTAGACTTTA AAGAATAAAG TCTTGGGAG 2460
 GTCTCACGGT GTAGAGAGGA GCTTGTAGGC CACCCGCACAA AATTACACC AGAGGGAAAT 2520
 CTCGTCGAA GGACACTCAC GGCAGTCTG GATCACCTGT GTATGTCAAC AGAAGGGATA 2580
 CCGTCTCCTT GAAGAGGAAA CTCTGTCACT CCTCATGCCT GTCTAGCTCA TACACCCATT 2640
 TCTCTTIGCT TCACAGGTT TAAACTGGTT TTTGTCATAC TGCTATATAA TTCTCTGTCT 2700
 CTCTCTGTT ATCTCTCCCC TCCCTCCCT CCCCCTCTTC TCCATCTCCA TTCTTGTAA 2760
 TTTCTCATC CCTCCATCTC AATCCCGTAT CTACGCACCC CCCCCCCCCC AGGCAAAGCA 2820
 GTGCTCTGAG TATCACATCA CACAAAAGGA AACAAAGCGA AACACACAAA CCAGCCTCAA 2880
 CTTACACTTG GTTACTCAAAGA AGAACAAAGAG TCAATGGTAC TTGTCTTAGC GTTTGGAAG 2940
 AGGAAAACAG GAACCCACCA AACCAACCAA TCAACCAAAC AAAGAAAAAA TTCCACAAATG 3000
 AAAGAATGTA TTTTGTCTTT TTGCATTTG GTGTATAAGC CATCAATATT CAGCAGGAAATG 3060
 ATTCCCTTCTT TAAAAAAAAT AAATGTGGAG GAAAGTAGAA ATTTACCAAG GTTGTGGCC 3120
 CAGGGCGTTA AATTACACAGA TTTTTTAAAC GAGAAAACACAGAAGAA GCTACCTCAG 3180
 GTGTTTTAC CTCAGCACCT TGCTCTTG TGCTCTTAG AGATTTGTA AAGCTGATAG 3240
 TTGGAGCAATT TTTTATTTT TTTAATAAA ATGAGTTGGA AAAAAAATAA GATATCAACT 3300
 GCCAGCGTGG AGAAGGTGAC AGTCCAAGTG TGCAACAGCT GTTCTGAATT GTCTCCGCT 3360
 AGCCAAGAAC CNATATGGCC TTCTTTGGA CAAACCTTGA AAATGTTAT TT 3412

<210> 7
 <211> 1946
 <212> DNA
 <213> Homo sapiens
 <220>
 <400> 7

C2
 GCTGTAGCGG AGGGGCTGGG GGGCTGCTCT GTCCCTTCC TTGCGCGCTG CGGCCTCAGC 60
 CCACCCAGAG GCCGGGGTGG GAGGGCGAGT GCTCAGCTTC CGGGGTTAGG AGCCGGAAAA 120
 TTCAAATCCG AAATATTCCA CCCCAGCTCC GATGGGAAGT ACTGGACAGC CTGCTGGCTC 180
 AGTATGGTAC AGTAGAGAAC TGTGAGGAGC TGAAACACCGA GAGTGGAGACG GCAGTGGTGA 240
 ATGTCACCTA TTCCAACCGG GAGCAGACCA GGCAAGCCAT CATGAAGCTG AATGCCACC 300
 AGTTGGAGAA CCATGCCCTG AAGGTCTCT ACATCCCCGA TGAGCAGATA GCACAGGGAC 360
 CTGAGAATGG GCGCCGAGGG GGCTTGGCT CTCGGGGTCA GCCCCGCCAG GGCTCACCTG 420
 TGGCAGCGGG GGCCCCAGCC AAGCAGCAGC AAGTGGACAT CCCCCCTTCGG CTCCTGGTGC 480
 CCACCCAGTA TGTGGGTGCC ATTATTGGCA AGGAGGGGGC CACCATCCGC AACATCACAA 540
 AACAGACCCA GTCCAAGATA GACGTGCATA GGAAGGAGAA CGCAGGTGCA GCTGAAAAG 600
 CCATCAGTGT GCACTCCACC CCTGAGGGCT GCTCCCTCCGC TTGTAAGATG ATCTTGGAGA 660
 TTATGCATA AGAGGCTAAAG GACACAAAAA CGGCTGACGA GTTCCCCCTG AAGATCCTGG 720
 CCCATAATAA CTTTGTAGGG CGTCTCATTC GCAAGGAAGG ACGGAACCTG AAGAAGGTAG 780
 AGCAAGATAC CGAGACAAAAA ATCACCATCT CCTCGTTGCA AGACCTTACC CTTTACAACC 840
 CTGAGAGGAC CATCACTGTG AAGGGGGCCA TCGAGAATTG TTGCAGGGCC GAGCAGGAAA 900
 TAATGAAGAA AGTCGGGAG GCCTATGAGA ATGATGTGGC TGCCATGAGC TCTCACCTGA 960
 TCCCTGGCCT GAACCTGGCT GCTGTAGGTC TTTTCCCGAC TTCACTCCAGC GCAGTCCCGC 1020
 CGCCTCCAG CAGCGTTACT GGGGCTGTC CCTATAGCTC CTTTATGCAAG GCTCCCGAGC 1080
 AGGAGATGGT GCAGGTGTTT ATCCCCGCC AGGCAGTGGG CGCCATCATC GGCAAGAAGG 1140
 GGCAGCACT CAAACAGCTC TCCCGGTTG CCAGCGCCTC CATCAAGATT GCACCACCCG 1200

AAACACCTGA CTCCAAAGTT CGTATGGTTA TCATCACTGG ACCGCCAGAG GCCCAATTCA 1260
 AGGCTCAGGG AAGAATCTAT GCCAAACCTCA AGGAGGAGAA CTCTTGGT CCCAAGGAGG 1320
 AAGTGAAGCT GGAGACCCAC ATACGTGTGC CAGCCTCAGC AGCTGGCCGG GTCATTGGCA 1380
 AAGGTGGAAA AACGGTGAAC GAGTTGCAGA ATTTGACGGC AGCTGAGGTG GTAGTACCAA 1440
 GAGACCAGAC CCCTGATGAG AACGACCCAG TCATCGTGAA AATCATCGGA CATTCTATG 1500
 CCAGTCAGAT GGCTAACCGG AAGATCCGAG ACATCCTGGC CCAGGTTAAG CAGCAGCATC 1560
 ACAAGGGACAG GAGTAACCGAG GCCCAGGCAC CGAGGAAGTG ACCAGCCCCCT CCCTGTCCCT 1620
 TNGAGTCCAG GACAACAAACG GGCAGAAATC GAGAGTGTGC TCTCCCCGGC AGGCCTGAGA 1680
 ATGAGTGGGA ATCCGGGACA CNTGGGGCGG GCTGTAGATC AGGTTTGCCC ACTTGATTGA 1740
 GAAAGATGTT CCAGTGAGGA ACCCTGATCT NTCAGCCCCA AACACCCACC CAATTGGCCC 1800
 AACACTGTNT GCCCCCTGGG GTGTAGAAA TTNTAGCGCA AGGCACCTTT AAACGTGGAT 1860
 TGTTAAAGA AGCTCTCCAG GCCCCACCAA GAGGGTGGAT CACACCTCAG TGGGAAGAAA 1920
 AATAAAATT CCTTCAGGTT TTAAAAA 1946

<210> 8
 <211> 3283
 <212> DNA
 <213> Homo sapiens
 <220>
 <400> 8

C2
 C4

GGCAGCGGAG GAGGGCAGGA GCGCCGGGT A CGGGGCCGGG GGAGCCGCGG GCTCTCGGGG 60
 AAGAGACCGA TGATGAACAA GCTTTACATC GGGAAACCTGA GCCCCGCCGT CACCGCCGAC 120
 GACCTCCGGC AGCTCTTGG GGACAGGAAG CTGCCCCCTGG CGGGACAGGT CCTGCTGAAG 180
 TCCGGCTACG CCTTCGTGGA CTACCCCGAC CAGAACTGGG CCATCCGCGC CATCGAGACC 240
 CTCTCGGGTA AAGTGGATT GCATGGAAA ATCATGGAAG TTGATTACTC AGTCTCTAAA 300
 AAGCTAAGGA GCAGGAAAAT TCAGATTGCA AACATCCCTC CTCACCTGCA GTGGGAGGTG 360
 TTGGATGGAC TTTGGCTCA ATATGGGACA GTGGAGAATG TGGAAACAAGT CAACACAGAC 420
 ACAGAAACCG CCGTGTCAA CGTCACATAT GCAACAAAGAG AAGAAGCAAA AATAGCCATG 480
 GAGAAGCTAA GCGGGCATCA GTTTGAGAAC TACTCCTTCA AGATTTCTCA CATCCGGAT 540
 GAAGAGGTGA GCTCCCTTC GCCCCCTCAG CGAGGCCAGC GTGGGGACCA CTCTCCCGG 600
 GAGCAAGGCC ACGCCCCCTGG GGGCACTTCT CAGGCCAGAC AGATTGATT CCCGCTGCGG 660
 ATCCTGGTCC CCACCCAGTT TGTTGGTCCC ATCATGGAA AGGAGGGCTT GACCATAAAG 720
 AACATCACTA AGCAGACCCA GTCCCCGGGATA GATATCCATA GAAAAGAGAA CTCTGGAGCT 780
 GCAGAGAACGCTGTCACCAT CCATGCCACC CCAGAGGGGA CTTCTGAAGC ATGCCGCATG 840
 ATTCTGAAA TCATGAGAA AGAGGCAGAT GAGACCAAAC TAGCCGAAGA GATTCCCTG 900
 AAAATCTGG CACACAATGG CTTGGTTGGA AGACTGATTG GAAAAGAAGG CAGAAATTG 960
 AAGAAAATTG AACATGAAAC AGGGACCAAG ATAACAATCT CATCTTGCA GGATTGAGC 1020
 ATATACAACC CGGAAAGAAC CATCACTGTG AAGGGCACAG TTGAGGCCTG TGCCAGTGC 1080
 GAGATAGAGA TTATGAAGAA GCTGCGTGAG GCCTTGAAA ATGATATGCT GGCTGTTAAC 1140
 ACCCACTCCG GATACTTCTC CAGCTGTAC CCCCCATCACC AGTTGGCCC GTTCCCGCAT 1200
 CATCACTCTT ATCCAGAGCA GGAGATTGTG AATCTCTTCA TCCCAACCCCA GGCTGTGGGC 1260
 GCCATCATCG GGAAGAAGGG GGCACACATC AAACAGCTGG CGAGATTCCGC CGGAGCCTCT 1320
 ATCAAGATTG CCCCTGCGGA AGGCCAGAC GTCAGCGAAA GGATGGTCAT CATCACCAGGG 1380
 CCACCGGAAG CCCAGTCAA GGGCCAGGGGA CGGAATCTTG GGAAACTGAA AGAGGAAAAC 1440
 TTCTTTAACCC CCAAAGAAGA AGTGAAGCTG GAAGCGCATCA TCAGAGTGCC CTCTTCCACA 1500
 GCTGGGGGG TGATTGGCAA AGGTGGCAAG ACCGTGAACG AACTGCAGAA CTTAACCAAGT 1560
 GCAGAAGTCA TCGTGCCTCG TGACCAAACG CCAGATGAAA ATGAGGAAGT GATCGTCAGA 1620
 ATTATCGGGC ACTTCTTTGC TAGCCAGACT GCACAGCGCA AGATCAGGGAA AATTGTACAA 1680
 CAGGTGAAGC AGCAGGAGCA GAAATACCT CAGGGAGTCG CCTCACAGCG CAGCAAGTGA 1740
 GGCTCCCACA GGCACCCAGCA AAACAACCGA TGAATGTAGC CTTCCAACA CCTGACAGAA 1800
 TGAGACCAAA CGCAGCCAGC CAGATCGGGA GCAAACCAA GACCATCTGA GGAATGAGAA 1860
 GTCTGCGGAG GCGGCCAGGG ACTCTGCCGA GGCCTTGAGA ACCCCAGGGG CCGAGGAGGG 1920
 GCGGGGAAGG TCAGCCAGGT TTGCCAGAAC CACCGAGGCC CGCCTCCCGC CCCCCAGGGC 1980
 TTCTGCAGGC TTCAAGCCATC CACTTCACCA TCCACTCGGA TCTCTCTGA ACTCCCACGA 2040
 CGCTATCCCT TTTAGTTGAA CTAACATAGG TGAACGTGTT CAAAGCCAAG CAAAATGCAC 2100
 ACCCTTTTC TGTGGCAAAT CGTCTCTGTA CATGTGTGTA CATATTAGAA AGGGAAAGATG 2160
 TTAAGATATG TGGCCTGTGG GTTACACAGG GTGCCCTGCAG CGGTAATATA TTTTAGAAAT 2220
 AATATATCAA ATAATCAAC TAACTCCAAT TTTTAATCAA TTATTAATT TTCTTCTTT 2280

TTAAAGAGAA AGCAGGCTTT TCTAGACTTT AAAGAATAAA GTCTTTGGGA GGTCTCACGG 2340
TGTAGAGAGG AGCTTGAGG CCACCCGCAC AAAATTCAAC CAGAGGGAAA TCTCGTCGGA 2400
AGGACACTCA CGGCAGTCT GGATCACCTG TGTATGTCAA CAGAAGGGAT ACCGTCTCCT 2460
TGAAGAGGAA ACTCTGTAC TCCATGCCTG TGTCTAGCTC ATACACCCAT TTCTCTTGC 2520
TTCACAGGTT TTAAACTGGT TTTTGCATA CTGCTATATA ATTCTCTGTC TCTCTCTGTT 2580
TATCTCTCCC CTCCCTCCCC TCCCCCTTCTT CTCCATCTCC ATTCTTTGA ATTTCCCTCAT 2640
CCCTCCACT CAATCCCGTA TCTACGCACC CCCCCCCCCC CAGGCAAAGC AGTGCTCTGA 2700
GTATCACATC ACACAAAAGG AACAAAAGCG AAACACACAA ACCAGCCTCA ACTTACACTT 2760
GGTTACTCAA AAGAACAAAGA GTCAATGGTA CTTGTCCTAG CGTTTTGGAA GAGGAAAACA 2820
GGAACCCACC AAACCAACCA ATCAACCAAA CAAAGAAAAA ATTCACAAAT GAAAGAATGT 2880
ATTTTGTCTT TTTGATTTT GGTGTATAAG CCATCAATAT TCAGCAAATAT GATTCCCTTC 2940
TTTAAAAAAA AAAATGTGGA GGAAAGTAGA AATTACCAA GTTGTGTCGCG CCAGGGCGTT 3000
AAATTCAACAG ATTTTTTAA CGAGAAAAAC ACACAGAAGA AGCTACCTCA GGTGTTTTA 3060
CCTCAGCACC TTGCTCTGT GTTTCCCTTA GAGATTTGT AAAGCTGATA GTGGAGCAT 3120
TTTTTTATT TTTAATAAA AATGAGTTGG AAAAAAAATA AGATATCAAC TGCCAGCCTG 3180
GAGAAGGTGA CAGTCCAAGT GTGCAACAGC TGTTCTGAAT TGCTTCCGC TAGCCAAGAA 3240
CCNATATGGC CTTCTTTGG ACAAACCTTG AAAATGTTA TTT 3283

<210> 9
<211> 21
<212> DNA
<213> Homo sapiens
<220>
<400> 9
gaagtatct tcaaggacgc c 21

<210> 10
<211> 22
<212> DNA
<213> Homo sapiens
<220>
<400> 10
ctgcaagggg ttttgtggg cg 22

<210> 11
<211> 22
<212> DNA
<213> Homo sapiens
<220>
<400> 11
tccttgcgcg ctgcggcctc ag 22

02
w/
<210> 12
<211> 23
<212> DNA
<213> Homo sapiens
<220>
<400> 12
ccaaactggc gccattcagc ttc 23

<210> 13
<211> 22
<212> DNA
<213> Homo sapiens
<220>
<400> 13
gcttttggg gacaggaagg tc 22

<210> 14
<211> 22

<212> DNA
<213> Homo sapiens
<220>
<400> 14
gacgttgaca acggcggtt ct 22

<210> 15
<211> 12
<212> DNA
<213> artificial sequence
<220>
<221> adaptor
<222> 1...12
<400> 15
aatttgcgtt ga 12

<210> 16
<211> 12
<212> DNA
<213> artificial sequence
<220>
<221> adaptor
<222> 1...12
<400> 16
aatttgcgttca tg 12

<210> 17
<211> 12
<212> DNA
<213> artificial sequence
<220>
<221> adaptor
<222> 1...12
<400> 17
aattttccct cg 12

C2
<210> 18
<211> 24
<212> DNA
<213> artificial sequence
<220>
<221> adaptor
<222> 1...24
<400> 18
agcactctcc agccctctcac catg 24

<210> 19
<211> 24
<212> DNA
<213> artificial sequence
<220>
<221> adaptor
<222> 1...24
<400> 19
accgacgtcg actatcatg catg 24

<210> 20
<211> 24

<212> DNA
<213> artificial sequence
<220>
<221> adaptor
<222> 1...24
<400> 20

aggcaactgt gctatccgag catg 24

<210> 21
<211> 8
<212> DNA
<213> artificial sequence
<220>
<221> adaptor
<222> 1...8
<400> 21

gtgagagg 8

<210> 22
<211> 8
<212> DNA
<213> artificial sequence
<220>
<221> adaptor
<222> 1...8
<400> 22

catggatg 8

12
2
✓<210> 23
<211> 8
<212> DNA
<213> artificial sequence
<220>
<221> adaptor
<222> 1...8
<400> 23

ctcggtata 8